Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18039877 | 0.85 | MAPT (0.54) | ALDH1A1TSHRLMNAMAPTSMN1; SMN2 | |
| SCHEMBL18039931 | 0.84 | ALDH1A1 (0.57) | ALDH1A1TSHRLMNAPOLBMAPT | |
| SCHEMBL5606028 | 0.81 | KDM1A (0.48) | ALDH1A1RAB9AL3MBTL1TSHRNPC1 | |
| SCHEMBL12719906 | 0.79 | ALDH1A1 (0.62) | ALDH1A1RAB9AL3MBTL1TSHRNPC1 | |
| SCHEMBL408106 | 0.79 | ALDH1A1 (0.62) | ALDH1A1RAB9ATSHRNPC1MAPT | |
| SCHEMBL11454925 | 0.78 | LMNA (0.54) | ALDH1A1L3MBTL1LMNAMAPTHSD17B10 | |
| SCHEMBL1127670 | 0.78 | L3MBTL1 (0.63) | ALDH1A1RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL15569388 | 0.78 | MAPT (0.62) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL441034 | 0.78 | ALDH1A1 (0.60) | ALDH1A1RAB9ATSHRNPC1MAPT | |
| SCHEMBL3959932 | 0.77 | GNAI3 (0.54) | ALDH1A1RAB9AL3MBTL1TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166594-B2 | Antibacterial activity | AVENTIS PHARMA S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| US-20030149004-A1 | Streptogramin derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. | 2003-08-07 | — | — | US | disclosed |
| US-6569854-B1 | Virginamycins | AVENTIS PHARMA S.A. (FR) | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149004-A1 | Streptogramin derivatives, their preparation and compositions containing them | MRPL21, ABHD5, APEH | ALDH1A1 4296/4885RAB9A 2288/4885L3MBTL1 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.